Article, News
Prescient Therapeutics announces share purchase plan to raise $8 million
Prescient Therapeutics Ltd (ASX:PTX) managing director and CEO Steven Yatomi-Clarke speaks with Proactive’s Elisha Newell about the company’s announcement of a share purchase plan (SPP), looking…
Article, News
Prescient Therapeutics (ASX:PTX) to progress deep cancer-treatment pipeline with capital raise
Clinical-stage oncology firm Prescient Therapeutics (ASX: PTX) announces a Share Purchase Plan (SPP) to raise AU$8.0 million. Funds raised from the SPP will be used for the…
Article, News
Prescient launches capital raise to progress pipeline of cancer therapies
Clinical stage oncology company Prescient Therapeutics to progress its deep pipeline of innovative cancer therapies with capital raise. The company is looking to raise $8…
Article, News
Prescient Therapeutics launches share purchase plan to raise $8 million
Clinical-stage oncology company developing personalised therapies Prescient Therapeutics (ASX:PTX) has announced a Share Purchase Plan (SPP) targeting to raise $8 million.
Article, News
Those who invested in Prescient Therapeutics (ASX:PTX) three years ago are up 307%
We think that it’s fair to say that the possibility of finding fantastic multi-year winners is what motivates many investors. Not every pick can be…
Article, News
Prescient Therapeutics to progress innovative pipeline of cancer treatments with capital raise
Prescient Therapeutics (ASX: PTX) has launched a capital raising targeting $8 million to maintain its momentum in developing its pipeline of innovative cancer and cell therapies…
Article, News
Prescient Therapeutics (ASX:PTX) to raise $8m for cancer treatment therapies
Prescient Therapeutics (PTX) is looking to raise $8 million via a share purchase plan (SPP) to progress its PTX-100 and PTX-200 cancer treatment therapies.
Article, News
Prescient (ASX: PTX) signs off FY22 with solid progress in clinical pipeline
Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) is working towards expanding its next-generation cell immunotherapy program. At the same time, Prescient is advancing major clinical programs, PTX-100 and…
Article, News
Prescient signs cell manufacturing deal ahead of OmniCAR trials
An Australian company developing personalised therapies for cancer has joined forces with a specialist cell therapy manufacturer to bolster its capabilities in the lead-up to…